Literature DB >> 8879378

Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues.

A M Dingemans1, J van Ark-Otte, P van der Valk, R M Apolinario, R J Scheper, P E Postmus, G Giaccone.   

Abstract

BACKGROUND: The recently discovered LRP protein has been shown to be involved in drug resistance and possibly in detoxification processes.
MATERIALS AND METHODS: To study the relation between LRP expression and exposure to cigarette smoke, LRP immunoreactivity was evaluated in 39 paraffin embedded normal lung tissues derived from patients operated on for pneumothorax, and related to amount of pack years smoked. We also studied the LRP protein expression in 36 non-small-cell lung cancer (NSCLC) samples and related the expression to patient characteristics and survival. Furthermore 17 lung tumor samples (10 NSCLC and 7 SCLC) derived from patients treated with chemotherapy were analysed in order to investigate the relation between LRP or MRP expression and the patient's response to chemotherapy.
RESULTS: In the normal lung tissues, LRP intensity levels were not correlated to the amount of pack years smoked, although a trend was seen for higher LRP intensity levels in patients who smoked more than 10 pack years. LRP expression was significantly higher in NSCLC samples than in SCLC samples, and all SCLC samples displayed very low LRP expression. Within NSCLC, squamous cell and adenocarcinomas had higher LRP expression than large cell undifferentiated and mixed tumors. In NSCLC patients LRP expression was not a prognostic factor for survival. At initial analysis LRP expression levels did not predict for the response to chemotherapy. Only 3 out of 17 patients expressed MRP, and all SCLC samples were MRP negative.
CONCLUSIONS: Striking different expression levels were seen between NSCLC and SCLC for both LRP and MRP. In a preliminary analysis LRP expression was not predictive for response to chemotherapy in lung cancer patients. In pneumothorax patients LRP levels were not correlated with the amount of pack years smoked.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879378     DOI: 10.1093/oxfordjournals.annonc.a010681

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  13 in total

1.  Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP.

Authors:  M A Izquierdo; G L Scheffer; A B Schroeijers; M C de Jong; R J Scheper
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

Review 2.  Drug resistance in lung cancer.

Authors:  Manish Shanker; David Willcutts; Jack A Roth; Rajagopal Ramesh
Journal:  Lung Cancer (Auckl)       Date:  2010-05-08

3.  Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues.

Authors:  A B Schroeijers; G L Scheffer; M J Flens; G A Meijer; M A Izquierdo; P van der Valk; R J Scheper
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

4.  Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy.

Authors:  Wenfeng Huang; Yan Mao; Yongzi Zhan; Jianfeng Huang; Xiangping Wang; Penghui Luo; L I Li; Dunchang Mo; Qiong Liu; Huimin Xu; Changjie Huang
Journal:  Oncol Lett       Date:  2015-11-13       Impact factor: 2.967

5.  Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.

Authors:  Walter Berger; Ulrike Setinek; Peter Hollaus; Thomas Zidek; Elisabeth Steiner; L Elbling; H Cantonati; Johannes Attems; Andrea Gsur; Michael Micksche
Journal:  J Cancer Res Clin Oncol       Date:  2005-01-27       Impact factor: 4.553

6.  Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer.

Authors:  J-J Yeh; N-Y Hsu; W-H Hsu; C-H Tsai; C-C Lin; J-A Liang
Journal:  Lung       Date:  2005 May-Jun       Impact factor: 2.584

7.  Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.

Authors:  J F Chiou; J A Liang; W H Hsu; J J Wang; S T Ho; A Kao
Journal:  Lung       Date:  2003       Impact factor: 2.584

Review 8.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

9.  Using technetium-99m tetrofosmin chest imaging to predict taxol-based chemotherapy response in non-small cell lung cancer but not related to lung resistance protein expression.

Authors:  C-M Shih; Y-C Shiau; J-J Wang; S-T Ho; A Kao
Journal:  Lung       Date:  2003       Impact factor: 2.584

10.  Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure.

Authors:  Consolación Melguizo; Jose Prados; Raquel Luque; Raúl Ortiz; Octavio Caba; Pablo J Alvarez; Beatriz Gonzalez; Antonia Aranega
Journal:  Int J Mol Sci       Date:  2012-12-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.